CALCHealthcare · BiotechnologyThe 4 Wall Street analysts covering CalciMedica, Inc. hold a median 12-month price target of $30 — +2379.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CalciMedica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CALC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +2379.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | Guggenheim | Initiates | Buy | $9.00 |
| 5 Mar 2026 | Oppenheimer | Maintains | Outperform | $20 → $10 |
| 5 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 29 Jan 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 July 2024 | Oppenheimer | Maintains | Outperform | — |
| 9 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2024 | Oppenheimer | Maintains | Outperform | — |
| 13 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Feb 2024 | JonesTrading | Initiates | Buy | — |
| 13 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CALC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 42% of US stocks
Cheaper than 64% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CalciMedica, Inc. has a market value of $8.5M and an enterprise value of $1.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$21.2M.
Free cash flow in the twelve months to 30 June 2026: −$19.1M.
Trailing P/E: 0.3×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CalciMedica, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CalciMedica, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CalciMedica Inc. (CALC) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
Why it matters — CALC watchers may note the change in Zacks’ assessment of the company’s earnings prospects.
CalciMedica reported third-quarter 2026 financial results and provided clinical and corporate updates. The company anticipates Auxora Phase 1b proof-of-concept data in pulmonary hypertension and a CM5480 IND submission in mid-2027.
Why it matters — The update gives CALC watchers timelines for two anticipated clinical and development milestones.
CalciMedica announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9:30 a.m.
Why it matters — The appearance gives CALC watchers a scheduled opportunity to hear from company management.
CalciMedica announced that its management will present and participate in one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage biopharmaceutical firm developing CRAC channel inhibition therapies, disclosed this participation on September 8, 2026.
Why it matters — Conference participation offers CalciMedica a platform to present its pipeline to investors, which could increase visibility among current and potential shareholders.
CalciMedica announced it will effect a one-for-five reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. on August 27, 2026. The company is a clinical-stage biopharmaceutical firm developing CRAC channel inhibition therapies.
Why it matters — A reverse stock split changes the number of shares outstanding and the per-share price, so CALC shareholders would want to note the revised share count and price structure.
The 4 Wall Street analysts covering CalciMedica, Inc. have a median 12-month price target of $30, with estimates ranging from $9 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering CalciMedica, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CalciMedica, Inc. 37 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, CalciMedica, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +2379.3% from the last close, and Ticker Nerd's factor model ranks CalciMedica, Inc. 37 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CalciMedica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CALC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $75 over the next 12 months.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases.
The most recent item we track (Zacks Investment Research, 12 Nov 2026): "What Makes CalciMedica Inc. (CALC) a New Buy Stock". CalciMedica Inc. (CALC) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.
CEO Dr. A. Rachel Leheny Ph.D. · 16 employees · United States · https://calcimedica.com